63 phenotypes from 6 alleles in 6 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Aspadeaf14/Aspadeaf14 BALB/c-Aspadeaf14	abnormal auditory brainstem response waveform shape	J:211825
	ataxia	J:211825
	normal behavior/neurological phenotype	J:211825
	brain vacuoles	J:211825
	decreased startle reflex	J:211825
	hyperactivity	J:211825
	impaired coordination	J:211825
	increased or absent threshold for auditory brainstem response	J:211825
	spongiform encephalopathy	J:211825
	tremors	J:211825
Aspanur7/Aspanur7 involves: C57BL/6J	abnormal brain morphology	J:226682
	abnormal brain white matter morphology	J:226682
	abnormal enzyme/coenzyme level	J:226682
	abnormal gait	J:143201
	abnormal myelination	J:143201
	abnormal oligodendrocyte morphology	J:143201
	abnormal sphingolipid level	J:226682
	astrocytosis	J:143201, J:226682
	ataxia	J:143201, J:226682
	axon degeneration	J:143201, J:226682
	brain vacuoles	J:143201, J:226682
	decreased body size	J:85113, J:143201
	decreased body weight	J:226682
	decreased locomotor activity	J:85113, J:143201, J:226682
	decreased vertical activity	J:226682
	demyelination	J:226682
	enlarged lateral ventricles	J:143201
	impaired coordination	J:143201, J:226682
	lethargy	J:85113
	premature death	J:226682
	seizures	J:143201, J:226682
	spongiform encephalopathy	J:143201, J:226682
	tremors	J:85113, J:143201, J:226682
Aspatm1a(EUCOMM)Wtsi/Aspatm1a(EUCOMM)Wtsi involves: C57BL/6J * C57BL/6N	abnormal gait	J:172582
	abnormal muscle tone	J:172582
	decreased anxiety-related response	J:172582
	decreased body size	J:172582
	decreased body weight	J:172582
	decreased locomotor activity	J:172582
	gliosis	J:172582
	impaired coordination	J:172582
	jerky movement	J:172582
	muscle hypertonia	J:172582
	muscle weakness	J:172582
	paralysis	J:172582
	spongiform encephalopathy	J:172582
Aspatm1b(EUCOMM)Wtsi/Aspatm1b(EUCOMM)Wtsi C57BL/6N-Aspatm1b(EUCOMM)Wtsi/Ieg	abnormal cornea morphology	J:211773
	abnormal gait	J:211773
	abnormal lens morphology	J:211773
	corneal opacity	J:211773
	decreased exploration in new environment	J:211773
	decreased food intake	J:211773
	decreased grip strength	J:211773
	decreased locomotor activity	J:211773
	decreased prepulse inhibition	J:211773
	decreased startle reflex	J:211773
	decreased vertical activity	J:211773
	hyperactivity	J:211773
	increased circulating alkaline phosphatase level	J:211773
	increased fasting circulating glucose level	J:211773
	increased mean corpuscular volume	J:211773
	limb grasping	J:211773
Aspatm1c(EUCOMM)Wtsi/Aspatm1c(EUCOMM)Wtsi involves: C57BL/6 * C57BL/6J * C57BL/6N * SJL	no abnormal phenotype detected	J:172582
Aspatm1Mata/Aspatm1Mata involves: 129S5/SvEvBrd	abnormal brainstem morphology	J:89100
	abnormal diencephalon morphology	J:89100
	abnormal gait	J:89100
	abnormal pain threshold	J:89100
	abnormal retina ganglion layer morphology	J:89100
	abnormal retina nerve fiber layer morphology	J:89100
	abnormal synaptic neurotransmitter level	J:89099
	ataxia	J:89100
	decreased body length	J:89099
	decreased body weight	J:89099, J:89100
	decreased bone mineral content	J:89099
	decreased bone mineral density	J:89099
	decreased bone mineral density of lumbar vertebrae	J:89099
	decreased gamma-aminobutyric acid level	J:89099
	decreased glutamic acid level	J:89099
	decreased total body fat amount	J:89099
	increased aspartic acid level	J:89099
	lethargy	J:89100
	megacephaly	J:89099, J:89100
	premature death	J:89100
	preweaning lethality, incomplete penetrance	J:89100
	spongiform encephalopathy	J:89100
	tremors	J:89100